Universal Health Cl B saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 69 to 72.
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks compares to the rest of the market.
Decades of market research reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Universal Health Cl B can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Universal Health Cl B is now considered extended and out of buy range after clearing a 182.92 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings-per-share growth declined in the company's latest report from 70% to 45%, but the top line rose from 10% to 11%.
The company holds the No. 2 rank among its peers in the Medical-Hospitals industry group. Tenet Healthcare is the top-ranked stock within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
